English
|
Spanish
Login
Register
The content on this site is intended for healthcare professionals only
Menu
Home
News
Journal
Video
e
learning
Conferences
About us
Keyword
Breast
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
Bone
Brain & nervous system
Haematology oncology
Hepatobiliary pancreatic
Paediatric
Neuroendocrine
Sarcomas
News
Latest news
Sign up for news alerts
Submit your news
Explore
Bone
Brain & nervous system
Breast
Colorectal & gastro
Haematology oncology
Head & neck
Hepatobiliary pancreatic
Lung & pleura
Melanoma & skin
Neuroendocrine
Ovary & gynaecology
Paediatric
Prostate & urology
Sarcomas
Journal information
Journal home
Charges
Editorial board
Founding editors
Editor-in-chief
Contact us
Author information
Submit article
Author guidelines
Editorial policies
Copyright information
Why publish with us
Reviewer information
Reviewer guidelines
Memberships
Videos
Recent videos
Sign up
Explore
Bone
Brain & nervous system
Breast
Colorectal & gastro
Haematology oncology
Head & neck
Hepatobiliary pancreatic
Lung & pleura
Melanoma & skin
Neuroendocrine
Ovary & gynaecology
Paediatric
Prostate & urology
Sarcomas
Conferences
Latest conferences
Sign up for latest coverage
Submit your event
About
e
cancer
About
e
cancer
Contact us
Support us
Work with us
Home
News
Journal
Video
e
learning
Conferences
About us
Keyword
Breast
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
+
-
Bone
Brain & nervous system
Haematology oncology
Hepatobiliary pancreatic
Paediatric
Neuroendocrine
Sarcomas
PARP inhibitors show promise for hard-to-treat breast cancers
2009 ASCO Annual Meeting
29 May - 2 Jun 2009
Please rate this video
The information in this video was of interest to me
The information in this video is likely to improve my clinical practice or research
I would recommend this video to my colleagues
Published:
25 Jun 2009
Views:
12697
Rating:
Save
Rate video
Dr. Andrew Tutt - Breakthrough Breast Cancer Research Unit, Kings College London, UK
A study reports that women with BRCA deficient advanced breast cancer experienced tumour shrinkage after receiving the PARP inhibitor olaparib as a single agent.
Categories:
Breast
Related Videos
Intraoperative ultrasound is accurate for guiding breast conservative surgery in...
Dr Antonio Esgueva - Clinica Universidad de Navarra, Madrid, Spain,
24 Nov 2022
Addressing women’s cancers: an economic evaluation of breast and cervical cancer...
Dr Mary Nyangasi - Head of the National Cancer Control Programme, Nairobi, Kenya
23 Nov 2022
Long-term breast cancer risk after benign breast disease in population-based scr...
Dr Marta Roman - Hospital del Mar Medical Research Institute, Barcelona, Spain
18 Nov 2022
EPIC study: Pre-existing cardiometabolic diseases impact cancer stage
Dr Anna Jansana - International Agency for Research on Cancer (IARC), Lyon, Fran...
17 Nov 2022
Individualised breast cancer risk assessment model for BreastScreen Norway
Dr Javier Louro - Hospital del Mar Medical Research Institute, Barcelona, Spain.
17 Nov 2022
Choosing wisely: Breast cancer
Dr Anupama Mane- Jehangir hospital, Pune, India
24 Oct 2022
Complex technologies for advanced diagnosis and precision medicine in oncology
Dr Joaquin Mateo - Vall d’Hebron Institute of Oncology, Barcelona, Spain
24 Oct 2022
Intraoperative Radiotherapy
Dr Mahima Pant - National Academy for Medical Sciences (NAMS), Kathmandu, Nepal
25 Sep 2022
Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced br...
Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA
21 Sep 2022
More from
e
cancer
